Redmond Kristin J, Schaub Stephanie K, Lo Sheng-Fu Larry, Khan Majid, Lubelski Daniel, Bilsky Mark, Yamada Yoshiya, Fehlings Michael, Gogineni Emile, Vajkoczy Peter, Ringel Florian, Meyer Bernhard, Amin Anubhav G, Combs Stephanie E, Lo Simon S
Department of Radiation Oncology and Molecular Radiation Sciences, The Johns Hopkins University, Baltimore, MD 21287, USA.
Department of Radiation Oncology, The University of Washington, Seattle, WA 98195, USA.
Cancers (Basel). 2023 Apr 18;15(8):2359. doi: 10.3390/cancers15082359.
Chordomas are rare tumors of the embryologic spinal cord remnant. They are locally aggressive and typically managed with surgery and either adjuvant or neoadjuvant radiation therapy. However, there is great variability in practice patterns including radiation type and fractionation regimen, and limited high-level data to drive decision making. The purpose of this manuscript was to summarize the current literature specific to radiotherapy in the management of spine and sacral chordoma and to provide practice recommendations on behalf of the Spine Tumor Academy. A systematic review of the literature was performed using the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) approach. Medline and Embase databases were utilized. The primary outcome measure was the rate of local control. A detailed review and interpretation of eligible studies is provided in the manuscript tables and text. Recommendations were defined as follows: (1) consensus: approved by >75% of experts; (2) predominant: approved by >50% of experts; (3) controversial: not approved by a majority of experts. Expert consensus supports dose escalation as critical in optimizing local control following radiation therapy for chordoma. In addition, comprehensive target volumes including sites of potential microscopic involvement improve local control compared with focal targets. Level I and high-quality multi-institutional data comparing treatment modalities, sequencing of radiation and surgery, and dose/fractionation schedules are needed to optimize patient outcomes in this locally aggressive malignancy.
脊索瘤是胚胎脊髓残余组织的罕见肿瘤。它们具有局部侵袭性,通常采用手术以及辅助或新辅助放射治疗。然而,在实际治疗模式上存在很大差异,包括放疗类型和分割方案,且缺乏用于指导决策的高级别数据。本手稿的目的是总结目前关于脊柱和骶骨脊索瘤放疗管理的文献,并代表脊柱肿瘤学会提供实践建议。采用系统评价和Meta分析的首选报告项目(PRISMA)方法对文献进行系统评价。使用了Medline和Embase数据库。主要结局指标是局部控制率。在手稿的表格和正文中提供了对符合条件研究的详细综述和解读。建议定义如下:(1)共识:超过75%的专家认可;(2)多数:超过50%的专家认可;(3)有争议:未得到多数专家认可。专家共识支持剂量递增对于脊索瘤放疗后优化局部控制至关重要。此外,与局部靶区相比,包括潜在微小浸润部位的综合靶区可改善局部控制。需要一级和高质量的多机构数据来比较治疗方式、放疗和手术的顺序以及剂量/分割方案,以优化这种局部侵袭性恶性肿瘤患者的治疗结局。